Skip to Content

American Funds New Perspective 529F CNPFX

Medalist Rating as of | See American Funds Investment Hub
  • NAV / 1-Day Return 57.87  /  +0.10 %
  • Total Assets 133.0 Bil
  • Adj. Expense Ratio
    0.860%
  • Expense Ratio 0.860%
  • Distribution Fee Level Below Average
  • Share Class Type No Load
  • Category Global Large-Stock Growth
  • Investment Style Large Growth
  • Min. Initial Investment 250
  • Status Open
  • TTM Yield 1.05%
  • Turnover 17%

USD | NAV as of Feb 27, 2024 | 1-Day Return as of Feb 27, 2024, 11:13 PM GMT+0

Morningstar’s Analysis CNPFX

Will CNPFX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A Manager Retirement and Addition on American Funds New Perspective Does Not Change Our View

null Stephen Welch

Stephen Welch

Analyst Note

American Funds’ parent Capital Group announced that veteran manager Jonathan Knowles will step off American Funds New Perspective on Jan. 2, 2024, and retire from the firm on April 1, 2024. Knowles has spent 18 of his 31 years at Capital Group managing this strategy. In November, Anne-Marie Peterson and Kohei Higashi will officially join the management team, bringing the total number of named managers to 11. While Knowles’ retirement is a loss, it is one that Capital Group is equipped to handle. These changes do not alter the strategy’s High People rating or its Morningstar Medalist Ratings.

Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CNPFX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 23.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Capital Group Central Cash Fund

5.73 7.3 Bil
Cash and Equivalents

Microsoft Corp

4.92 6.2 Bil
Technology

Novo Nordisk A/S Class B

3.19 4.0 Bil
Healthcare

Broadcom Inc

2.64 3.4 Bil
Technology

Meta Platforms Inc Class A

2.62 3.3 Bil
Communication Services

Taiwan Semiconductor Manufacturing Co Ltd

2.27 2.9 Bil
Technology

Tesla Inc

2.06 2.6 Bil
Consumer Cyclical

Eli Lilly and Co

1.76 2.2 Bil
Healthcare

ASML Holding NV

1.42 1.8 Bil
Technology

AstraZeneca PLC

1.35 1.7 Bil
Healthcare